Rationale and design of a study to assess the safety and efficacy of rNAPc2 in COVID-19: the Phase 2b ASPEN-COVID-19 trial (2022)
- Authors:
- Autor USP: NICOLAU, JOSÉ CARLOS - FM
- Unidade: FM
- DOI: 10.1016/j.ahj.2021.12.010
- Subjects: COVID-19; TROMBOSE; REPLICAÇÃO VIRAL
- Agências de fomento:
- Language: Inglês
- Imprenta:
- Source:
- Título do periódico: American heart journal
- ISSN: 0002-8703
- Volume/Número/Paginação/Ano: v. 246, p. 136-143, 2022
- Este periódico é de assinatura
- Este artigo é de acesso aberto
- URL de acesso aberto
- Cor do Acesso Aberto: green
-
ABNT
HESS, Connie N. et al. Rationale and design of a study to assess the safety and efficacy of rNAPc2 in COVID-19: the Phase 2b ASPEN-COVID-19 trial. American heart journal, v. 246, p. 136-143, 2022Tradução . . Disponível em: https://doi.org/10.1016/j.ahj.2021.12.010. Acesso em: 19 abr. 2024. -
APA
Hess, C. N., Capell, W. H., Bristow, M. R., Ruf, W., Szarek, M., Morrow, D. A., et al. (2022). Rationale and design of a study to assess the safety and efficacy of rNAPc2 in COVID-19: the Phase 2b ASPEN-COVID-19 trial. American heart journal, 246, 136-143. doi:10.1016/j.ahj.2021.12.010 -
NLM
Hess CN, Capell WH, Bristow MR, Ruf W, Szarek M, Morrow DA, Nicolau JC, Graybill CA, Marshall D, Hsia J. Rationale and design of a study to assess the safety and efficacy of rNAPc2 in COVID-19: the Phase 2b ASPEN-COVID-19 trial [Internet]. American heart journal. 2022 ; 246 136-143.[citado 2024 abr. 19 ] Available from: https://doi.org/10.1016/j.ahj.2021.12.010 -
Vancouver
Hess CN, Capell WH, Bristow MR, Ruf W, Szarek M, Morrow DA, Nicolau JC, Graybill CA, Marshall D, Hsia J. Rationale and design of a study to assess the safety and efficacy of rNAPc2 in COVID-19: the Phase 2b ASPEN-COVID-19 trial [Internet]. American heart journal. 2022 ; 246 136-143.[citado 2024 abr. 19 ] Available from: https://doi.org/10.1016/j.ahj.2021.12.010 - Ticagrelor versus clopidogrel in patients with STEMI treated with fibrinolysis TREAT trial
- Ticagrelor vs Clopidogrel After Fibrinolytic Therapy in Patients With ST-Elevation Myocardial Infarction: A Randomized Clinical Trial (vol 3, pg 391, 2018)
- Effects of Dapagliflozin on Symptoms, Function, and Quality of Life in Patients With Heart Failure and Reduced Ejection Fraction Results From the DAPA-HF Trial
- Efficacy and Safety of Dapagliflozin in Heart Failure With Reduced Ejection Fraction According to Age Insights From DAPA-HF
- Effect of alirocumab on mortality after acute coronary syndromes an analysis of the ODYSSEY OUTCOMES randomized clinical trial
- Predicting risk of cardiovascular events 1 to 3 years post-myocardial infarction using a global registry
- Long-term ticagrelor for secondary prevention in patients with prior myocardial infarction and no history of coronary stenting: insights from PEGASUS-TIMI 54
- Two-year outcomes among stable high-risk patients following acute MI. Insights from a global registry in 25 countries
- Anti-Thrombotic Therapy to Ameliorate Complications of COVID-19 (ATTACC): Study design and methodology for an international, adaptive Bayesian randomized controlled trial
- Rationale and design of the long-Term rIsk, clinical manaGement, and healthcare Resource utilization of stable coronary artery dISease in post-myocardial infarction patients (TIGRIS) study
Informações sobre o DOI: 10.1016/j.ahj.2021.12.010 (Fonte: oaDOI API)
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
